Topical 5% imiquimod for the therapy of actinic cheilitis

Journal of the American Academy of Dermatology

Volumn 47, Issue 4, 2002, Pages 497-501

  Smith, Kathleen J ^a   Germain, Margeruite ^b   Yeager, Josef ^b   Skelton, Henry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; VALACICLOVIR;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CHEILITIS; CLINICAL ARTICLE; CRYOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; EXPERIENCE; FEMALE; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

EID: 0036788796     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.126266     Document Type: Article

References (19)

1. Laws RA, Wilde JL, Grabaski WJ. Surgical pearl: scroll-shaped electrode for electrodesiccation of actinic cheilitis. J Am Acad Dermatol 2000;42:827-8.
2. Cooper I, Lee A. Cryostatic congelation: a system for producing a limited controlled region cooling or freezing of biologic tissue. J Nerv Ment Dis 1961;33:259-63.
3. Kuwahara RT, Raspberry RD. Cryosurgery acne attachment for actinic cheilitis. Dermatol Surg 2000;26:899-902.
4. Neder A, Nahlieli O, Kaplan I. CO2 laser used in surgical treatment of actinic cheilitis. J Clin Laser Med Surg 1992;10:373-5.
5. Defresne RG, Curlin MU. Actinic cheilitis. A treatment review. Dermatol Surg 1997;23:15-21.
6. Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. J Dermatol Surg Oncol 1994;20:449-56.
7. Edward L. Imiquimod in clinical practice. J Am Acad Dermatol 2000;43(Suppl):S12-S17.
8. Kray MK, Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg 2000;26:577-8.
9. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
10. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease, J Am Acad Dermatol 2001;44:462-70.
11. Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, Sulindac: potential applications for this combination of immunotherapy. Dermatol Surg 2001;27:143-6.
12. Pehoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in an HIV-1 positive man. Arch Dermatol 2001;137:14-6.
13. Tyring S. Imiquimod applied topically: a novel immune response modifier. Skin Therapy Lett 2001;6:1-4.
14. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RMA, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9.
15. Tomai MA, Birmachu W, Case MT, Gerster JF, Gibson SJ, Imbertson LM, et al. Imiquimod: in vivo and in vitro characteristics and toxicology. In: Aly R, Beutner KR, Maibach H, editors. Cutaneous infection and therapy. New York: Marcel Dekker; 1997. p. 405-15.
16. Wagner TL, Ahone CL, Couture AM, Gibson SJ, Miller RL, Smith RM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10-9.
17. Trinchieri G, Scott P. Interleukin 12: a proinflammatory cytokine with immunoregulatory functions. Res immunol 1995;146:423-31.
18. Suzuki H, Wang B, Shivji GM, Paola S, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhan's cells. J Invest Dermatol 2000;114:135-41.
19. Burns RP, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000;94:13-23.